Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Molecular Basis Of Cancer-therapy-induced Cardiotoxicity: Introducing MicroRNA Biomarkers For Early Assessment Of Subclinical Myocardial Injury.

Hardip Sandhu, H. Maddock
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs.
This paper references
10.1200/JCO.1993.11.6.1118
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
A. Forastiere (1993)
10.1046/J.1365-201X.1999.00562.X
Post-ischaemic dysfunction does not correlate with release of cardiac troponin T in isolated rat hearts.
T. Kawakami (1999)
10.7326/0003-4819-126-10-199705150-00020
Anthracycline-induced cardiotoxicity.
K. Shan (1996)
10.1111/j.1601-0825.2009.01604.x
Exosomes from human saliva as a source of microRNA biomarkers.
A. Michael (2010)
10.1073/pnas.1206432109
Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function
B. C. Bernardo (2012)
10.1016/s0021-9258(17)38400-4
Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism.
R. D. Armstrong (1986)
10.1073/pnas.0606663104
Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy
J. McMullen (2007)
10.1016/S1388-9842(01)00231-8
Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology
W. Remme (2002)
10.1100/tsw.2009.128
Urinary Exosomes
I. Dimov (2009)
Induction of cyclooxygenase - 2 and activation of nuclear factor - κ B in myocardium of patients with congestive heart failure
S. C. Wong (1998)
10.1038/sj.emboj.7600385
MicroRNA genes are transcribed by RNA polymerase II
Yoontae Lee (2004)
10.1158/0008-5472.CAN-04-1443
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
10.1038/cr.2011.132
Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice
J. Wang (2012)
10.1021/JA00738A045
Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
M. Wani (1971)
10.1038/277665a0
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
10.1046/j.1365-2796.2002.00951.x
Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction
T. Nousiainen (2002)
10.1016/S0014-2999(01)00765-8
Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review.
E. D. De Beer (2001)
10.1074/jbc.M109.082610
MicroRNA-15b Modulates Cellular ATP Levels and Degenerates Mitochondria via Arl2 in Neonatal Rat Cardiac Myocytes*
H. Nishi (2009)
10.1016/J.VASCN.2013.01.110
Protein biomarkers of drug-induced cardiotoxicity in the isolated heart: Building a multi-scale approach
Brandon Borders (2013)
10.1016/j.mrfmmm.2011.03.004
Extracellular microRNA: a new source of biomarkers.
A. Etheridge (2011)
10.1016/j.ceb.2009.01.014
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
M. Eck (2009)
10.1373/CLINCHEM.2005.050153
N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?
M. Sandri (2005)
10.1038/ncb1929
Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity
Qinxi Li (2009)
Cardiotoxicity of the antiproliferative compound fluorouracil.
K. Becker (1999)
Cyclophosphamide for clinical renal and hepatic transplantation.
T. Starzl (1973)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
10.1093/eurheartj/ehq167
Circulating microRNAs are new and sensitive biomarkers of myocardial infarction
Yuri D'Alessandra (2010)
10.1200/JCO.2001.19.13.3163
Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study.
A. Mertens (2001)
10.1136/bmj.3.5669.503
Clinical Evaluation of Adriamycin, a New Antitumour Antibiotic
G. Bonadonna (1969)
Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro.
L. Bosch (1958)
10.1002/cncr.10833
Childhood cancer survival in Europe and the United States
G. Gatta (2002)
10.1016/j.cell.2007.03.030
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Y. Zhao (2007)
10.1016/0041-008X(91)90336-D
Mitochondrial regulation of superoxide by Ca2+: an alternate mechanism for the cardiotoxicity of doxorubicin.
E. Chacón (1991)
10.1016/S0960-9822(02)00809-6
Identification of Tissue-Specific MicroRNAs from Mouse
M. Lagos-Quintana (2002)
10.1101/gr.082701.108
Most mammalian mRNAs are conserved targets of microRNAs.
Robin C Friedman (2009)
10.1007/978-1-4613-2303-7_12
Complications of Acute Myocardial Infarction
E. Antman (1986)
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
J. Extra (1993)
Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.
H. M. Olson (1974)
10.1073/PNAS.89.22.10578
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
C. T. Guy (1992)
The effects of nitrogen mustard on DNA template activity in purified DNA and RNA polymerase systems.
R. Ruddon (1968)
10.1007/s00432-008-0372-8
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. F. Broeyer (2008)
10.1586/14737140.4.4.679
Current treatment options for endometrial cancer
A. Santin (2004)
10.1177/030089160108700317
Acute Cardiotoxicity during Capecitabine Treatment: A Case Report
A. Bertolini (2001)
10.1016/j.nmd.2010.11.012
Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1
R. Perbellini (2011)
10.1253/CIRCJ.CJ-10-0457
Assessment of plasma miRNAs in congestive heart failure.
Y. Fukushima (2011)
10.1016/j.ejphar.2009.06.065
Rational drug design.
S. Mandal (2009)
10.3109/10428194.2012.679360
Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy
D. El-Sharkawi (2012)
10.1016/S1535-6108(02)00039-9
Smart drugs: tyrosine kinase inhibitors in cancer therapy.
L. Shawver (2002)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
R. Pietras (1994)
10.1080/02841860903229124
Cardiotoxicity induced by tyrosine kinase inhibitors
George S Orphanos (2009)
10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E
Cardiotoxicity of 5‐fluorouracil in combination with folinic acid in patients with gastrointestinal cancer
C. Schöber (1993)
10.1161/CIRCGENETICS.111.959841
Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction
M. Zile (2011)
10.1146/annurev-biochem-060308-103103
Regulation of mRNA translation and stability by microRNAs.
M. Fabian (2010)
10.2147/CE.S6003
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
E. Jabbour (2010)
10.1016/0959-8049(95)00575-7
5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure?
T. Lieutaud (1996)
daunorubicin in lung cancer
A. D. Santin (2004)
10.1073/pnas.0710558105
An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133
N. Liu (2007)
10.1161/circgenetics.110.958975
Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage
Y. Kuwabara (2011)
10.1016/S1388-9842(01)00201-X
Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis
M. I. Gharib (2002)
Chemotherapy of ovarian cancer: past and present.
Young Rc (1975)
10.1016/j.bbrc.2009.11.005
Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction.
J. Ai (2010)
10.1074/jbc.M308033200
Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes*
C. Lim (2004)
10.1016/j.ijgo.2008.04.008
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
A. Santin (2008)
10.1007/BF01966490
Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H]FMLP binding
M. Iannone (2005)
10.1038/ng1725
The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation
Jian-Fu Chen (2006)
10.2165/00003495-199957040-00003
Cardiotoxicity of the Antiprolif erative Compound Fluorouracil
K. Becker (2012)
10.1093/ANNONC/MDF167
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
L. Kremer (2002)
10.1111/j.1582-4934.2008.00613.x
Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis
C. van Solingen (2009)
10.1073/pnas.0805038105
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
E. van Rooij (2008)
10.1200/JCO.2001.19.7.1926
Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
D. Green (2001)
10.1080/00365519909168330
Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM).
A. Wu (1999)
10.1093/eurheartj/ehq013
Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans.
Guokun Wang (2010)
10.1200/JCO.1991.9.9.1704
Cardiac disturbances during the administration of taxol.
E. Rowinsky (1991)
10.1096/fasebj.13.2.199
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
G. Minotti (1999)
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
E. Rowinsky (1988)
10.1016/0163-7258(88)90004-6
Metabolism of oxazaphosphorines.
N. Sládek (1988)
10.1128/MCB.9.3.1165
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
R. Hudziak (1989)
10.1038/nature07511
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
T. Thum (2008)
Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins
A. H. Wu (1999)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
S. Zhou (2001)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1016/0163-7258(90)90088-J
Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.
H. Keizer (1990)
10.2337/db11-0952
MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients
S. Greco (2012)
10.1101/GAD.1543507
A complex system of small RNAs in the unicellular green alga Chlamydomonas reinhardtii.
T. Zhao (2007)
10.7326/0003-4819-111-4-273
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
W. Mcguire (1989)
[Preliminary results of the therapeutic effectiveness in leukemia and malignant tumors in children of a new antineoplastic antibiotic: "daunomycin"].
L. Massimo (1967)
Plasma microRNA-361-5p as a biomarker of chronic heart failure
C. Chen (2010)
The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients
S. E. Lipshultz (1993)
10.1136/hrt.2010.208967.613
e0613 Plasma microRNA-361-5p as a biomarker of chronic heart failure
C. Chen (2010)
daunorubicin in lung cancer
A. D. Santin (2004)
10.1634/theoncologist.2008-0230
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
J. Ross (2009)
10.3322/CANJCLIN.40.6.355
The impact of childhood cancer on the United States and the world
W. A. Bleyer (1990)
Blood constituent changes in fasted swine.
Baetz Al (1971)
10.4161/cc.6.8.4124
PI3K(p110α) Inhibitors as Anti-Cancer Agents: Minding the Heart
J. McMullen (2007)
10.1016/J.MRFMMM.2006.12.006
Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure.
I. Pogribny (2007)
10.1016/S0968-0004(97)01061-X
Phosphoinositide 3-kinases: a conserved family of signal transducers.
B. Vanhaesebroeck (1997)
10.1001/JAMA.1991.03470120074036
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
10.1177/030089166304900603
[ACTION OF DAUNOMYCIN ON THE NUCLEIC METABOLISM OF EHRLICH ASCITES TUMOR].
R. Silvestrini (1963)
10.1056/NEJMRA044389
Tyrosine kinases as targets for cancer therapy.
D. S. Krause (2005)
10.1101/SQB.1994.059.01.046
Cellular senescence and cancer.
J. Barrett (1994)
10.1177/000456320103800501
Measurement of Cardiac Troponins
P. Collinson (2001)
10.1038/nrc1819
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M. Cully (2006)
10.1038/ncb1596
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
H. Valadi (2007)
10.1172/JCI18921
C-reactive protein: a critical update.
M. Pepys (2003)
10.1159/000046508
Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity
H. Okumura (2000)
10.1124/MOL.63.4.849
Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
J. Kwok (2003)
10.1371/journal.pone.0003148
Serum MicroRNAs Are Promising Novel Biomarkers
S. Gilad (2008)
10.1038/nm1446
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä (2006)
10.1172/JCI9083
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
B. Druker (2000)
10.1001/ARCHINTE.1981.00340060066015
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
10.1016/0014-2964(70)90014-9
Preliminary clinical screening with daunorubicin in lung cancer.
Y. Kenis (1970)
10.1056/NEJM199506293322602
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
S. Lipshultz (1995)
10.1038/nm1569
The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2
B. Yang (2007)
Effects of taxol on human neutrophils.
R. L. Roberts (1982)
10.1182/BLOOD-2004-10-3856
Iron trafficking in the mitochondrion: novel pathways revealed by disease.
I. Napier (2005)
10.7326/0003-4819-118-1-199301010-00006
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Z. Quezado (1993)
10.1038/42648
Signalling through the lipid products of phosphoinositide-3-OH kinase
A. Toker (1997)
10.1053/EUHJ.2000.2305
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.
J. Alpert (2000)
10.1007/s002800050788
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model
H. Guchelaar (1998)
10.1161/01.RES.85.5.446
Absence of troponin I degradation or altered sarcoplasmic reticulum uptake protein expression after reversible ischemia in swine.
S. A. Thomas (1999)
10.1038/sj.onc.1202526
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
10.1042/CS20090645
A translational study of circulating cell-free microRNA-1 in acute myocardial infarction.
Y. Cheng (2010)
10.1007/978-1-4684-5607-3_11
Thymidylate synthase and fluorouracil.
K. Ivanetich (1988)
10.1016/S1040-8428(97)10007-5
Anthracycline-induced cardiotoxicity in children and young adults.
A. Giantris (1998)
10.1161/CIRCRESAHA.109.197517
MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation
Y. Cheng (2009)
10.1016/j.leukres.2010.04.016
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
Xin An (2010)
Differential transcription of miRNA species caused by doxorubicin induced cardiotoxicity
M. Gharanei (2012)
10.1055/S-0037-1615550
Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches.
J. Ruef (1999)
10.1172/JCI20317
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis.
O. Yamaguchi (2004)
10.1073/PNAS.77.3.1561
Taxol stabilizes microtubules in mouse fibroblast cells.
P. Schiff (1980)
10.1161/CIRCULATIONAHA.108.776831
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
M. Chen (2008)
10.1161/CIRCRESAHA.109.215566
Circulating MicroRNAs in Patients With Coronary Artery Disease
S. Fichtlscherer (2010)
10.1155/JBB/2006/69616
MicroRNAs in Gene Regulation: When the Smallest Governs It All
D. L. Ouellet (2006)
Ethyl methanesulfonate-induced reversion of bacteriophage T4rII mutants.
D. R. Krieg (1963)
10.1182/BLOOD.V96.1.307.013K47_307_313
Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.
E. Shacter (2000)
10.1073/PNAS.87.11.4275
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro.
H. Ito (1990)
10.1056/NEJM199103213241205
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
10.1126/SCIENCE.1114519
MicroRNA Expression in Zebrafish Embryonic Development
E. Wienholds (2005)
10.1002/cbf.1578
The relationship between cell membrane damage and lipid peroxidation under the condition of hypoxia‐reoxygenation: analysis of the mechanism using antioxidants and electron transport inhibitors
D. Yajima (2009)
Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer.
S. Frytak (1975)
10.1007/s00395-010-0123-2
MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction
B. Meder (2010)
10.1053/CTRV.2000.0175
Long-term chemotherapy-related cardiovascular morbidity.
M. T. Meinardi (2000)
10.1007/978-3-662-46875-3_100202
The Anticancer Drugs
W. Pratt (1979)
10.1093/CLINCHEM/45.7.1104
National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases.
A. Wu (1999)
10.1200/JCO.1991.9.7.1215
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
A. Braverman (1991)
10.1172/JCI36154
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.
T. Callis (2009)
10.1038/nrc2106
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
T. Force (2007)
10.1042/CS20100043
Gene expression profiling in whole blood of patients with coronary artery disease
C. Taurino (2010)
10.1001/JAMA.296.12.1518
An anniversary for cancer chemotherapy.
J. Hirsch (2006)
10.1038/nature03817
Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis
Y. Zhao (2005)
10.1126/SCIENCE.1139089
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
E. van Rooij (2007)
10.1016/0002-9610(63)90232-0
The initial clinical trial of nitrogen mustard.
A. Gilman (1963)
Experiments with some mouse tumors and leukemias.
J. Holland (1958)
10.1016/S0022-2836(66)80004-9
Inter-strand crosslinking of DNA by nitrogen mustard.
K. Kohn (1966)
10.1161/CIRCGENETICS.110.957415
Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease
M. Corsten (2010)
10.1080/01926230490261302
Serum Troponins as Biomarkers of Drug-Induced Cardiac Toxicity
K. Wallace (2004)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
10.1161/CIRCRESAHA.110.218297
MiR423-5p As a Circulating Biomarker for Heart Failure
A. J. Tijsen (2010)
10.1373/clinchem.2009.125310
Plasma miR-208 as a biomarker of myocardial injury.
Xu Ji (2009)
10.5555/URI:PII:009377549290034X
Taxol: the first of the taxanes, an important new class of antitumor agents.
E. Rowinsky (1992)
10.1016/S1567-4215(07)60006-X
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure.
T. Thum (2007)
The role of iron in doxorubicin-induced cardiomyopathy.
C. Myers (1998)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1177/106002809402800314
Fluorouracil Cardiotoxicity
A. Anand (1994)
10.1007/BF00918679
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
H. Shepard (2004)
10.1016/S0092-8674(04)00045-5
MicroRNAs Genomics, Biogenesis, Mechanism, and Function
D. Bartel (2004)
10.1111/j.1365-2141.2005.05759.x
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
Karlijn A Wouters (2005)
10.1182/BLOOD.V68.5.1114.BLOODJOURNAL6851114
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
M. Goldberg (1986)
10.1016/J.CANLET.2005.11.014
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Y. Park (2006)
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
D. B. Mendel (2003)
10.1200/JCO.2001.19.1.191
Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
L. Kremer (2001)
10.1161/CIRCRESAHA.111.244442
Inhibition of miR-15 Protects Against Cardiac Ischemic Injury
T. Hullinger (2012)
10.1034/J.1600-0773.2003.930301.X
Doxorubicin-induced cardiac mitochondrionopathy.
K. Wallace (2003)
10.1016/j.jacc.2012.02.033
Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease.
Quanfu Xu (2012)
10.1073/pnas.0804549105
Circulating microRNAs as stable blood-based markers for cancer detection
P. S. Mitchell (2008)
10.1016/S0065-2776(08)60379-X
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.
M. Pepys (1983)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1016/J.IJCARD.2007.02.003
BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity.
T. W. Vogelsang (2008)
10.1200/JCO.1997.15.4.1544
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.
J. Krischer (1997)
10.1200/JCO.1992.10.8.1245
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
A. Forastiere (1992)
Control of stress-dependent cardiac growth and gene expression by a microRNA
R. E. van (2007)
10.1038/nrg1328
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs
D. Bartel (2004)
10.1200/JCO.1997.15.4.1318
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
S. Swain (1997)
Studies on fluorinated pyrimidines. IV. Effects on nucleic acid metabolism in vivo.
P. Danneberg (1958)
10.1373/clinchem.2010.144121
Plasma microRNA 499 as a biomarker of acute myocardial infarction.
T. Adachi (2010)
10.1002/ijc.23501
miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells
Lin Xia (2008)
10.1002/AJH.10017
Detection of relapse in non‐Hodgkin's lymphoma: Role of routine follow‐up studies
A. Elis (2002)
10.1152/AJPHEART.00759.2003
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
X. Liu (2004)
10.1038/cdd.2009.153
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease
L. Elia (2009)
10.1161/01.CIR.0000013839.41224.1C
Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity
D. Sawyer (2002)
10.1016/j.bbrc.2008.11.059
Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.
Neil Ashley (2009)
10.1200/JCO.2006.09.1611
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter (2007)
10.1038/nrm2199
Signal integration in the endoplasmic reticulum unfolded protein response
D. Ron (2007)
10.1056/nejm200210033471426
Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
D. Muthu (2009)
Does wild-type p53 play a role in normal cell differentiation?
V. Rotter (1994)
10.1124/mol.108.050104
Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
B. Hasinoff (2008)
10.1016/j.cub.2007.06.068
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
G. Bommer (2007)
The comparative utilization of uracil-2-C14 by liver, intestinal mucosa, and Flexner-Jobling carcinoma in the rat.
C. Heidelberger (1957)
10.1016/S1734-1140(09)70018-0
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
T. Šimůnek (2009)
10.1161/CIRCULATIONAHA.104.482570
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
R. Vasan (2006)
10.2169/INTERNALMEDICINE.50.5129
Circulating microRNAs are promising novel biomarkers of acute myocardial infarction.
Rongrong Wang (2011)
10.1161/CIRCRESAHA.106.141986
MicroRNA Expression Signature and Antisense-Mediated Depletion Reveal an Essential Role of MicroRNA in Vascular Neointimal Lesion Formation
Ruirui Ji (2007)
5-Fluorouracil cardiotoxicity.
A. Lomeo (1990)
10.1016/s0021-9258(18)89465-0
Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells.
B. Dolnick (1985)
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. Broeyer (2008)
10.1016/j.ejheart.2004.03.009
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction
G. Daugaard (2005)
10.1046/j.1365-2141.2003.04288.x
Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration
S. Sohn (2003)
The taxoids. Comparative clinical pharmacology and therapeutic potential.
E. Eisenhauer (1998)
10.3109/02841869509093643
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
M. Cwikiel (1995)
10.1016/J.UROLONC.2008.11.009
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
P. Russo (2009)
10.1056/NEJMOA060655
Sorafenib in advanced clear-cell renal-cell carcinoma.
B. Escudier (2007)
10.1016/J.YJMCC.2004.12.013
Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes.
S. Rohrbach (2005)
Blood constituent changes in fasted swine.
A. Baetz (1971)
10.1016/S0891-5849(97)00025-7
Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity.
L. Gille (1997)
Docetaxel in combination chemotherapy for metastatic breast cancer.
D. Khayat (1997)
10.1016/S0027-5107(99)00010-X
Lipid peroxidation-DNA damage by malondialdehyde.
L. Marnett (1999)
10.1016/j.ccc.2014.03.010
Acute myocardial infarction.
A. Ibrahim (2014)
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
H. Lueck (1997)
Ca2+ transport by mitochondria and its possible role in the cardiac contraction-relaxation cycle.
Lehninger Al (1974)
10.1056/NEJM199304083281404
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
R. Fisher (1993)
10.1038/nature09412
MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis
S. Nicoli (2010)
10.7326/0003-4819-112-3-167
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
A. Dreyfuss (1990)
10.1371/journal.pone.0040395
Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment
Caterina Vacchi-Suzzi (2012)
10.1002/cncr.23460
Heart failure associated with sunitinib malate
A. Khakoo (2008)
10.1073/pnas.0608791103
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure
E. van Rooij (2006)
10.1016/0002-8703(83)90651-8
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
J. Mckillop (1983)
10.1016/S0925-4439(02)00144-8
Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis.
P. Green (2002)
10.1016/0163-7258(91)90086-2
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.
E. Rowinsky (1991)
10.1016/j.bbrc.2010.03.075
The peripheral blood mononuclear cell microRNA signature of coronary artery disease.
M. Hoekstra (2010)
10.1016/0304-419X(95)00002-W
Genetic analysis of cellular senescence.
P. Vojta (1995)
10.1007/s12012-009-9056-0
Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib
B. Hasinoff (2009)
10.1016/j.leukres.2009.08.031
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.
M. Breccia (2010)
10.1074/JBC.A111.801035
Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart.
Xiaobin Luo (2011)
10.1200/JCO.1996.14.3.737
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J. Baselga (1996)
10.1016/0014-2964(71)90056-9
Evidence for the inactivation and repair of the mammalian DNA template after alkylation by mustard gas and half mustard gas.
J. J. Roberts (1971)
10.1073/PNAS.84.20.7159
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
10.1186/1423-0127-18-22
Role of miR-1 and miR-133a in myocardial ischemic postconditioning
B. He (2010)
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
V. Pai (2000)
10.1016/J.CTRV.2003.07.003
Cardiotoxicity of cytotoxic drugs.
K. Schimmel (2004)
10.1152/physiolgenomics.00211.2009
MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients.
C. Voellenkle (2010)
10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia
C. Tan (1967)
Ca2+ Transport by Mitochondria and Its Possible Role in the Cardiac Contraction‐Relaxation Cycle
A. Lehninger (1974)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1126/SCIENCE.2885917
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma.
W. Sutow (1971)
10.1097/00000421-199910000-00009
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
C. Kuropkat (1999)
10.1200/JCO.1991.9.9.1692
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
E. Rowinsky (1991)
10.1161/CIRCHEARTFAILURE.109.913863
&bgr;-Thalassemia Cardiomyopathy: History, Present Considerations, and Future Perspectives
D. Kremastinos (2010)
10.1161/01.CIR.102.11.1216
It's time for a change to a troponin standard.
A. Jaffe (2000)
10.1126/SCIENCE.281.5381.1312
Caspases: enemies within.
N. Thornberry (1998)
Differential transcription of miRNA species caused by doxorubicin induced cardiotoxicity
M. Gharanei (2012)
10.1016/J.CCCN.2005.05.027
Evaluation of H-FABP as a marker of ongoing myocardial damage using hGH transgenic mice.
Hitoshi Naraoka (2005)
10.1053/HJ.1998.V136.89908
Elevated B-type natriuretic peptide levels after anthracycline administration.
T. Suzuki (1998)
10.1242/dev.002576
EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution
Maike Schmidt (2007)
10.1093/nar/gkl428
Comprehensive thermodynamic analysis of 3′ double-nucleotide overhangs neighboring Watson–Crick terminal base pairs
Amanda S. O'Toole (2006)
10.1097/00001622-199507000-00002
Cardiotoxicity and cardioprotection during chemotherapy.
H. Hochster (1995)
10.1074/JBC.274.28.19792
Oxidative Stress Inhibits Apoptosis in Human Lymphoma Cells*
Y. Lee (1999)
10.1200/JCO.1990.8.2.313
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.
N. Kemeny (1990)
10.1126/science.1174381
MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice
A. Bonauer (2009)
10.1016/J.BBAPAP.2005.07.040
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
P. Manley (2005)
10.1053/CTRV.1999.0128
Detection of anthracycline-induced cardiotoxicity.
M. T. Meinardi (1999)
10.1161/CIRCULATIONAHA.107.687947
MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure
T. Thum (2007)
10.1200/JCO.1990.8.11.1806
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
D. Nielsen (1990)
10.1006/EXCR.2000.4838
Induction of apoptosis by cancer chemotherapy.
S. Kaufmann (2000)
10.1152/AJPLUNG.1992.263.5.L511
Role of surface complexed iron in oxidant generation and lung inflammation induced by silicates.
A. Ghio (1992)
Marrow transplantation for leukemia and aplastic anemia.
E. Thomas (1976)
10.1161/01.CIR.91.1.10
Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.
N. Siveski-Iliskovic (1995)
10.1080/01926230500519816
Serum Chemical Biomarkers of Cardiac Injury for Nonclinical Safety Testing
Dana B. Walker (2006)
10.4155/fmc.13.11
Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
A. Ghigo (2013)
10.1016/J.TIG.2006.01.003
Genomics of microRNA.
V. Kim (2006)
10.1161/01.CIR.102.5.572
Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study.
T. Nakamura (2000)
10.1124/MOL.105.013383
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
X. Xu (2005)
Acute Myocardial Infarction. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine (Braunwald
E. M. Antman (2001)
High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography.
S. F. Gardner (1993)
10.1038/nrcardio.2012.142
Biomarkers: Pros and cons of high-sensitivity assays for cardiac troponin
E. Giannitsis (2012)
10.1007/s00109-008-0341-3
miRNAs at the heart of the matter
Z. Wang (2008)
10.1093/ANNONC/MDM223
Dasatinib: a new step in molecular target therapy.
A. Olivieri (2007)
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.
J. Yates (1973)
10.1152/ajpheart.01010.2008
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.
Y. Bian (2009)
10.1016/0891-5849(94)00159-H
Oxidative mechanisms in the toxicity of metal ions.
S. Stohs (1995)
10.1161/01.CIR.102.3.272
Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
A. Feldman (2000)
10.1073/PNAS.0506654102
miR-15 and miR-16 induce apoptosis by targeting BCL2.
A. Cimmino (2005)
10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V
Acute arrhythmogenicity of doxorubicin administration
J. Steinberg (1987)
10.1016/0092-8674(81)90270-1
Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis
K. Crossin (1981)
10.1016/S0140-6736(07)61865-0
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
T. F. Chu (2007)
10.1002/14651858.cd003917.pub2
Cardioprotective interventions for cancer patients receiving anthracyclines.
E. C. van Dalen (2005)
Overview of cardiac pathology in relation to anthracycline cardiotoxicity.
Ferrans Vj (1978)
10.1152/ajpheart.1998.274.5.H1684
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure.
A. Luchner (1998)
10.1093/cvr/cvq148
Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway
T. Horie (2010)
Biochemical markers of cardiac damage : from traditional enzymes to cardiac - specific proteins . IFCC Subcommittee on Standardization of Cardiac Markers ( S - SCM )
A. H. Wu (1999)
10.3310/HTA11270
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
J. Bryant (2007)
10.1152/AJPHEART.00738.2005
DNA damage is an early event in doxorubicin-induced cardiac myocyte death.
T. L'ecuyer (2006)
10.1161/01.CIR.98.2.100
Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.
S. C. Wong (1998)
10.1016/0891-5849(91)90192-6
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.
H. Esterbauer (1991)
10.1038/nsmb1167
RNA polymerase III transcribes human microRNAs
Glen M. Borchert (2006)
The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits.
M. Cwikiel (1995)
10.1111/j.1600-0609.1999.tb01734.x
Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non‐Hodgkin's lymphoma
T. Nousiainen (1999)
10.1016/j.yjmcc.2011.07.011
Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome.
Christian Widera (2011)
Effect of 5-fluorouracil substitution on the self-splicing activity of Tetrahymena ribosomal RNA.
P. Danenberg (1990)
Methods of using miRNA for preclinical / clinical screen to assess drug safety
B. He (2010)
10.1016/j.devcel.2009.10.013
A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance.
E. van Rooij (2009)
10.1016/0304-419X(96)00005-4
P53 and angiogenesis.
N. Bouck (1996)
10.1177/003591577306601240
Evolution of a practical policy for chemotherapy of carcinoma of the breast.
M. L. Sutton (1973)
10.2165/00002018-200022040-00002
Cardiotoxicity of Chemotherapeutic Agents
V. Pai (2000)
10.1101/GAD.1399806
Control of translation and mRNA degradation by miRNAs and siRNAs.
M. A. Valencia-Sanchez (2006)
10.1021/BI00357A063
Effects of 5-fluorouracil on globin mRNA synthesis in murine erythroleukemia cells.
T. Iwata (1986)
10.21608/mjfmct.2007.48836
Vitamin E and N-Acetylcysteine as Antioxidant Adjuvant Therapy in Children with Acute Lymphoblastic Leukemia
Y. Al-Tonbary (2007)
10.1056/NEJM197401242900404
Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.
Jeffrey A. Gottlieb (1974)



This paper is referenced by
10.1093/eurheartj/ehy365
Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications
P. Ferdinandy (2019)
Cardiovascular Diseases Associated with Pregnancy: Early Assessment
Hardip Sandhu (2015)
The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology
MEE TING REPOR (2020)
Cell communication via microRNA exchange between endothelial and tumour cells during anti-cancer neoadjuvant chemotherapy
Stella Dederen (2018)
10.1186/s12885-018-4015-4
Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients
P. Frères (2018)
MAKING MORE SENSITIVE DNA SENSORS USING GOLD NANOPARTICLES AND DNA-BASED AMPLIFICATION NETWORKS
Herbert Huttanus (2014)
10.1093/toxsci/kfv222
Paving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment.
Stéphanie F Glineur (2016)
10.1007/s12012-018-9457-z
Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab
F. Zhou (2018)
10.4172/2090-7214.1000E107
Insulin Resistance in Women with Polycystic Ovary Syndrome: Optimising treatment by Implementing an in vitro Insulin Resistance Organ Culture Model
H. Hu (2015)
10.1007/978-1-4939-0956-8_2
Translational bioinformatics approaches for systems and dynamical medicine.
Q. Yan (2014)
10.1016/j.yexcr.2016.10.019
Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma.
Xuren Gao (2016)
Assessing physiological .response to toxic industrial chemical exposure in megacities
Danielle L Ippolito (2016)
10.1161/CIRCRESAHA.116.308434
Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury.
J. Viereck (2017)
10.1038/s41598-019-48470-0
Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis
Ji Yoon Lee (2019)
10.3390/cells9041001
Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs
A. Sachinidis (2020)
10.1021/acs.jcim.7b00641
In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers
Chuipu Cai (2018)
10.1007/s11936-018-0641-z
Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment
Li-ling Tan (2018)
10.1021/pr501116c
Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics.
Yubo Li (2015)
10.1016/j.bmcl.2014.05.089
One-pot synthesis of cinnamylideneacetophenones and their in vitro cytotoxicity in breast cancer cells.
David J Weldon (2014)
10.1517/17425255.2014.954312
Noncoding RNA response to xenobiotic exposure: an indicator of toxicity and carcinogenicity
April K. Marrone (2014)
10.2217/bmm.15.50
Development and regulatory application of microRNA biomarkers.
J. Krauskopf (2015)
10.1002/med.21463
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Ping-Pin Zheng (2018)
10.1016/j.lfs.2018.12.018
Molecular mechanism involved in cyclophosphamide‐induced cardiotoxicity: Old drug with a new vision
A. Iqubal (2019)
10.1016/j.ejphar.2017.08.011
Attenuation of Sunitinib‐induced cardiotoxicity through the A3 adenosine receptor activation
Hardip Sandhu (2017)
10.2217/bmm.15.89
microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.
I. Koturbash (2015)
10.1007/978-981-15-1671-9_22
Circulating Non-coding RNAs and Cardiovascular Diseases.
Chenglin Zhao (2020)
10.4172/2090-7214.1000212
Cardiovascular Diseases Associated with Pregnancy: Early Assessment Using Non-Invasive MicroRNA Profiling
Hardip Sandhu (2015)
10.1007/s00395-018-0704-z
The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection—evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncology
S. Davidson (2018)
10.4172/2329-6607.1000183
Early Subclinical Biomarkers in Onco-Cardiology to Prevent Cardiac Death
Yajun Gu (2015)
Clinical Assessment of Cardiovascular Disorders by Cardiac Biomarkers
A. Gupta (2014)
10.1002/clc.22507
Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC‐ONC Study—A Single‐Center, Blinded, Randomized Controlled Trial
R. Chung (2016)
10.1016/j.toxrep.2020.01.001
microRNAs: Potential biomarkers of toxicity: A special issue of the journal Toxicology Reports
S. Sahu (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar